Menu

Pharma News

99 AA010633

Pfenex makes biosimilar deals with Alvogen and NT Pharma

Home/Pharma News | Posted 06/07/2018

US-based biotech firm Pfenex has made commercialization deals for its candidate teriparatide biosimilar (PF708) in China and in the US.

23 AA011020

Amneal and mAbxience make deal for bevacizumab biosimilar

Home/Pharma News | Posted 29/06/2018

US generics maker Amneal Pharmaceuticals (Amneal) and biosimilars specialist mAbxience, a subsidiary of Spanish healthcare firm Insud Pharma (formerly the Chemo Group), announced on 23 May 2018 that they have signed an exclusive licensing and supply agreement in the US for mAbxience’s candidate bevacizumab biosimilar.

104 MD001918

Strides and Apotex to merge Australian generics businesses

Home/Pharma News | Posted 22/06/2018

India-based generics manufacturer Strides Shasun (Strides) announced on 9 May 2018 that it had made an agreement with Canada-based Apotex to merge their Australian businesses.

10 AA008993

Sanofi to sell Zentiva generics arm to Advent

Home/Pharma News | Posted 18/05/2018

French drugmaker Sanofi announced on 17 April 2018 that it had entered into exclusive negotiations with Advent International (Advent) under which Advent would acquire Zentiva, Sanofi’s European generics business for Euros 1.9 billion.

15 AA010699

Mylan and Fujifilm Kyowa Kirin Biologics partner on adalimumab biosimilar

Home/Pharma News | Posted 04/05/2018

Fujifilm Kyowa Kirin Biologics announced on 11 April 2018 that it will partner with Mylan to commercialize its adalimumab biosimilar FKB327. Mylan will be granted exclusive commercialization rights for FKB327 in Europe.

132 AA011051

Fujifilm to acquire cell culture media companies

Home/Pharma News | Posted 27/04/2018

Fujifilm is expanding its ability to develop and manufacture biologicals by acquiring a pair of cell culture media businesses owned by Japan-based JXTG Holdings for a combined US$800 million.

Meeting V13F14

Stada resubmits biosimilar pegfilgrastim but stops adalimumab development

Home/Pharma News | Posted 13/04/2018

German generics giant Stada Arzneimittel (Stada) was informed on 2 March 2018 by Gedeon Richter (Richter) that the European Medicines Agency (EMA) has accepted the regulatory resubmission of its proposed pegfilgrastim biosimilar. However, in another press release the company announced that it was stopping development of its adalimumab biosimilar.

138 AA011155

Korea’s CJ Healthcare shares biosimilar technology with China

Home/Pharma News | Posted 06/04/2018

South Korea’s CJ HealthCare, announced that it has signed a contract with China’s NCPC GeneTech Biotechnology on 31 January 2018 to export CJ-40001, a biosimilar version of darbepoetin alfa which is used for the treatment of renal anaemia. South Korea has well-established guidelines for biosimilars [1], whilst China has finalized the technical guidance for the development and evaluation of copy biologicals in February 2015 [2].

138 AA011155

Biosimilar deals for Hikma and Lupin

Home/Pharma News | Posted 30/03/2018

Collaborations are once again the way forward when it comes to biosimilars. Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) made a licensing deal with South Korean biotechnology company Celltrion in December 2017.  In March 2018 Indian generics maker Lupin Pharmaceuticals (Lupin) made an agreement with the Council of Scientific and Industrial Research-National Chemical Laboratory (CSIR-NCL) and the Department of Science and Technology (DST).

Shaking hands V13D29

Mylan and Revance team up for botox biosimilar

Home/Pharma News | Posted 02/03/2018

US-based drugmaker Mylan announced on 28 February 2018 that it had made a deal with Revance Therapeutics to make a biosimilar of Allergan’s cosmetic blockbuster Botox (onabotulinumtoxinA).